A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Study acronym: ATTAIN-NOW
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 40 of 180 sites
  2. Site details revised at 35 of 180 sites
  3. Recruitment opened
    • Start date changed from estimate of Sep 2026 to Aug 26, 2026
    • Study sites: 179 to 180
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Hypertension
1,933 trials monitored
See 101 trials at risk
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
Trial Details
NCT Number NCT07794579
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Related terms Obesity, Abdominal, Overweight, Prediabetic State, Prehypertension
Enrollment 2,001 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov